AZN vs HIND

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

Vyome Holdings (HIND) presents a high-risk profile characterized by a catastrophic collapse in share price (-96.1% over 1 year) and severe operational inefficiency. While the Piotroski F-Score of 5/9 suggests a 'stable' baseline in terms of basic financial structure, this is overshadowed by an operating margin of -3707.35% and a massive earnings miss of -2736.4%. The company is trading at an unsustainable Price/Sales ratio of 48.08 despite revenue declining by 40.5% YoY, indicating a complete disconnect between valuation and fundamental performance.